Company / Profit Margin
Theravance Biopharma, Inc. Profit Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
98.5%
FY2025
5-year range
-386.9% / 98.5%
FY2021-FY2025
Trend
+212.5%
vs FY2024
Sector context
#4 of 146
Health Care
What the data says
Profit Margin changed +212% YoY in FY2025, a notable deviation from the 9-year average annual change of -240%.
Based on SEC 10-K filings.
98.5% in FY2025 with a 5-year CAGR of +485.4%. Top quartile in the Health Care sector.
Improved from -96.1% to 98.5% over the past 2 years.
Health Care sector context is included.
Profit Margin over time
Growth rates
- 3-Year Change
- +485.4pp
- 5-Year Change
- +485.4pp
- 10-Year Change
- -
Sector benchmark
Top 3% in Health CareTop 3% of 146This company 98.5% Sector average -796.3%
▼
+112.4% above sector average
Key checks
Key Insights
- Theravance Biopharma, Inc.'s profit margin has grown for 3 consecutive years.
- In FY2025, profit margin increased 212.5% year-over-year.
- Currently 894.8pp above the Health Care sector average.
- Lowest profit margin in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 98.5% | +212.5% |
| FY2024 | -87.6% | +8.8% |
| FY2023 | -96.1% | +75.2% |
| FY2022 | -386.9% | -7.3% |
| FY2021 | -360.6% | +6.8% |
| FY2020 | -386.9% | +79.1% |
| FY2019 | -1855.0% | -373.3% |
| FY2018 | -391.9% | +95.8% |
| FY2017 | -9245.4% | -2258.9% |
| FY2016 | -391.9% | +99.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026